Noboru Hiroi, Ph.D.

Albert Einstein College of Medicine of Yeshiva University

Curriculum Vitae
Date: April 28, 2015
Name: Noboru Hiroi, Ph.D.
Office Address: Albert Einstein College of Medicine
Golding 104
1300 Morris Park Avenue
Bronx, NY 10461
Tel: 718-430-3124
Fax: 718-430-3125
E-mail: noboru.hiroi@einstein.yu.edu
Citizenship:

Japanese citizen and US permanent resident (Green Card holder)

Education:

1981-1985
1985-1991

B.A.
Ph.D.

Waseda University, Tokyo, Japan (Psychology)
McGill University, Montreal, Canada(Psychology, Behavioral Neuroscience Program)

Postgraduate Training and Fellowship Appointments:
1991-1994
Post-doctoral Fellow (Laboratory of Ann M. Graybiel, Ph.D.)
Department of Brain and Cognitive Sciences,
Massachusetts Institute of Technology, Cambridge, MA
1994 summer
Post-doctoral Fellow (Laboratory of Norman M. White, Ph.D.),
Department of Psychology, McGill University, Montreal, Canada
1994-1995
Post-doctoral Associate (Laboratory of Eric J. Nestler, M.D., Ph.D.),
Department of Psychiatry, Yale University School of Medicine, New Haven,
CT
Professional Employment:
1995-1998:
1998-2005

2005-20112006-2009

Associate Research Scientist, Division of Molecular Psychiatry, Departmentof Psychiatry, Yale University School of Medicine, New Haven, CT
Assistant Professor of Psychiatry, Assistant Professor of Neuroscience,
Director of Laboratory of Molecular Psychobiology, Department of
Psychiatry and Behavioral Sciences and Department of Neuroscience, Albert
Einstein College of Medicine, Bronx, NY
Associate Professor of Psychiatry, Associate Professor of Neuroscience,
Director of Laboratory of Molecular Psychobiology, Department of
Psychiatry and Behavioral Sciences and Department of Neuroscience, Albert
Einstein College of Medicine, Bronx, NY
Visiting Scientist, RIKEN-Brain Science Institute (BSI), Wako, Saitama,
Japan.
1

Noboru Hiroi, Ph.D.
2011-present
2011-present

Board Certification:

Associate Professor. Department of Genetics, Albert Einstein College ofMedicine, Bronx, NY
Professor of Psychiatry, Professor of Neuroscience, Director of Laboratoryof Molecular Psychobiology, Department of Psychiatry and Behavioral
Sciences and Department of Neuroscience, Albert Einstein College ofMedicine, Bronx, NY

N/A

Professional Society Membership:
International:
Society for Neuroscience (Member, 1988-present)International Brain Research Organization (Member, 1988-present)
Society of Biological Psychiatry (Member, 2004-present)
American College of Neuropsychopharmacolgy(ACNP) (2013-present).
Psychiatric Research Society (Member, 2014-present)
22Q Society (Founding Member, 2014-present)Awards and Honors:
1981-1985
1985-1986
1986-1991
1986-1988
1991
1992-1994
1998
2001
2006
2006-2008
2007-2008
2008
2009
2010
2011
2013
2013
2014
2014
2014

Okuma Shigenobu Memorial Scholarship, Waseda University, Japan
Sankei Scholar
Government of Canada Award
Bindra Pre-doctoral Fellowship
Dean’s Honor List, McGill University
Human Frontier Science Program Fellow
NARSAD Young Investigator Award
The best poster prize, the 1st International Cajal Club Meeting, Madrid, Spain
Invited participant of Roche-Nature Medicine Translational Neuroscience
Symposium 9/18-19/2006, Palo Alto, CA
NARSAD Independent Investigator Award
Maltz NARSAD Investigator
Top 10 Reviewers for Biological Psychiatry in 2008
Top 10 Reviewers for Biological Psychiatry in 2009
Top 10 Reviewers for Biological Psychiatry in 2010
Top 10 Reviewers for Biological Psychiatry in 2011
#1 reviewer, Neuropsychopharmacology, 2013
Elected Full Member of the American College of
Neuropsychopharmacology (ACNP)Elected member of the Psychiatric Research Society
Ambassador, CINP
#1 reviewer, Neuropsychopharmacology, 20142

Noboru Hiroi, Ph.D.
Other Professional Activities:
NIH Study section:
2003
2004
2006
2007
2008
2009
2010
2010

2011
2011
2011

2011

2011

2012
2012

2012
2012
2012
2013
2013
2014
2014
2015

Ad-hoc Reviewer, NIDA study section for the Cutting-Edge Basic ResearchAwards (CEBRA).
Ad-hoc Reviewer, NIH study section (P50) Transdisciplinary Tobacco Use
Research Center (TTURC)
Ad-hoc Reviewer, NIH Special Emphasis Panel Study Section, ZDA1 MXSM (24)24Ad-hoc Reviewer, NCI PO1 review panel SubCommittee E, October 2007.
Ad-hoc Reviewer, NIH/NIDA study section, ZDA1 RXL-E(08)Ad-hoc Reviewer, NIH/NIDA study section, ZDA GXM-A (04), May 14,2009.
Ad-hoc reviewer, NIH/NIDA study section, B/START R03 Review Meeting
Dates: 03/10/2010, Meeting Identifier: 2010/05 ZDA1 GXM-A (02) 1
Ad-hoc reviewer, NIH/NCI study section, Disparities, Cancer Risk, andPrognostic Factors, Special Emphasis Panel , 9/28-29/2010 ZCA1 RPRB-7(J1)Ad-hoc reviewer, NIH/NIDA study section, Support Opportunity for
Addiction Research, 5/18-5/19/2011, ZRG1 IFCN-L (50) R
Ad-hoc reviewer, NIH/NIDA study section, 5/25/2011, 2011/10 ZDA1
GXM-A (02) 1.
Ad-hoc reviewer, Special Emphasis Panel/Scientific Review Group,
06/14/2011-06/15/2011, ZRG1 IFCN-A (03) Member Conflict:
Neuropharmacology (NMB).
Ad-hoc reviewer, Special Emphasis Panel/Scientific Review Group
2011/10 ZRG1 BBBP-V (02) Member Conflict: Biobehavioral Regulation,
Learning and Ethology, 7/11/2011.
Ad-hoc reviewer, NIH/NCI , Special Emphasis Panel/Scientific Review
Group Disparities, cancer risk, prevention and prognostic factors, 10/56/2011.
Ad-hoc reviewer, NIH/NCI , NCI P01 Special Emphasis Panel One ZCA1
RPRB-B (M1) 2/2-3/2012.
Ad-hoc reviewer, NIH/NCI , NCI P01 Special Emphasis Panel One, ZCA1
RPRB-7 (M1) R, SPORE in Lymphoma, Brain, Head/Neck and Lung
Cancers, and Sarcoma. 2/8/2012-2/9/2012. 2012/05
Ad-hoc reviewer, ZRG1 IFCN-H (03) M, Member Conflict: Integrative andFunctional Neuroscience Study section, 02/28/2012-02/29/2012
Ad-hoc reviewer, ZRG1 IFCN-Q 03 M, 6/19/2012-6/19/2012
Ad-hoc reviewer, ZRG1 IFCN-C (03) M Member Conflict SEP: Stress,
Nicotine and Reward, 12/5/2012
Ad-hoc reviewer, ZCA-RPRB-7(M1), 2/6/2013
Reviewer, BRLE, 6/10/2013
Ad-hoc reviewer, ZRG1 BBBP-V (02) M, 2/13-14, 2014
Ad-hoc reviewer, Developmental Brain Disorders (DBD) study section.
10/23-10/24, 2014.
Ad-hoc reviewer, Molecular Neurogenetics (MNG) study section, June 4-5,
2015
3

Noboru Hiroi, Ph.D.

External reviewer for faculty promotion: NIDA, 2009; Mount Sinai School of Medicine, 2009; Northwestern
University, 2011; New York University, 2011
Editorial Positions:
2008-Present Member, Editorial board of Neuropsychopharmacology, the official journal of
the American College of Neuropsychopharmacology.
2008-Present Member, Editorial board of Biological Psychiatry, the official journal of theSociety of Biological Psychiatry
2008-present Member, Editorial Advisory Board, The Open Neuropsychopharmacology
Journal
2011-present Member, Editorial Board, Current Psychopharmacology
2011-present Associate Editor, Nicotine & Tobacco Research, the official journal of theSociety for Research on Nicotine and Tobacco
Ad-hoc Reviewer of Journals:
Human Molecular Genetics
Biological Psychiatry
Journal of Neuroscience
Brain
Neuropsychopharmacology
Genes, Brain and Behavior
Journal of Comparative Neurology
International Journal of Neuropsychopharmacology
Journal of Neurochemistry
European Journal of Neuroscience
Neurobiology of Disease
Nicotine and Tobacco Research
Journal of Pharmacology and Experimental Therapeutics
Psychoneuroendocrinology
Brain Research
Behavioral Brain Research
Pharmacology, Biochemistry and Behavior
Biochemical Pharmacology
Molecular Medicine
Hippocampus
Acta histochemica
European Neuropsychopharmacology
Anatomical Record
Molecular Medicine
PlosOneAcademic and Institutional Committees:4

Noboru Hiroi, Ph.D.
2000-present Member, Addiction Psychiatry Fellowship Program, Department of Psychiatry
and Behavioral Sciences, Albert Einstein College of Medicine
2002-present
Faculty Coordinator, Psychiatric Scientist Track, Department of Psychiatry
and Behavioral Sciences, Albert Einstein College of Medicine
2004-2008
Senator, The senate of the Albert Einstein College of Medicine.
2006
Ad-hoc chair of the faculty promotions subcommittee, Albert Einstein
College of Medicine
2006-2007
Chair, Psychiatry Faculty Search Committee
2008-present
Member, the faculty promotions and appointments committee, Albert
Einstein College of Medicine
2009Ad-hoc external reviewer for the Appointments & Promotions Committee ofthe Mount Sinai School of Medicine.
2009
Ad-hoc external reviewer for the Appointments & Promotions Committee of
the National Institute on Drug Abuse (NIDA)/NIH.
2009-2010
Member, Departmental Planning Committee for Dean’s 2010 strategicplanning, Albert Einstein College of Medicine
2011-2012 Member, Department of Genetics, Training Grant Steering Committee, Albert
Einstein College of Medicine
Organizational Roles in Scientific Meetings:
2007-2009
Member, the Ziskind-Somerfeld Research Award Committee, the Society ofBiological Psychiatry
2015-2017
Member, the Membership Selection Committee, American College of
Neuropsychopharmacology (ACNP)
Consultationships:
2008-20092013

Consultant, Intracellular Therapies Inc. 3960 Broadway, New York NY
10032
Consultant, DaiNippon Sumitomo Pharmaceuticals, Inc, Osaka, Japan

Research:
Completed (over the past 5 years only):
R01DA013232“Intracellular Molecules of Nicotine Addiction”
Principal Investigator: Noboru Hiroi, Ph.D.
Agency, NIDA; Type, R01; Period, 8/1/00-4/30/05 (no cost-extension to 4/30/06)$750,000 (direct costs)
P01NS037409“Molecular Etiology of Early Onset Torsion Dystonia”
Principal Investigator: X. O. Breakefield and Laurie Ozelius, Ph.D.
Collaborator: Noboru Hiroi, Ph.D.
Agency, NINDS; Type, P01; Period, 6/14/04-6/30/07$31,856 (direct costs, 9% effort)
5

Noboru Hiroi, Ph.D.

“A human 22q11.2 segment and endophenotypes of schizophrenia in mice”
PI: Noboru Hiroi, Ph.D., NARSAD Maltz Investigator
Agency, NARSAD Independent Investigator Award; Period, 9/15/2006 - 9/14/2008$100,000 (total costs)
R21HD053114“22q11 Genes and Complex Behavior in Mice”
PI: Noboru Hiroi, Ph.D.
Agency, NICHD/NIMH/NINDS; Type, R21; Period, 02/01/2008 - 01/31/2010 (no cost extension to 1/31/2012)$275,000 (direct costs)
R01DA024330“Molecular Mechanisms of Nicotine Addiction and Extinction”
PI: Noboru Hiroi, Ph.D.
Agency, NIDA; Type, R01; Period, 9/20/2007 – 8/31/2012$980,080 (direct costs)
Active:1R01MH099660-01A1“COMT and Developmental Memory Capacity”
PI: Noboru Hiroi, Ph.D.
Agency, NIMH: Type, R01: Period, 1/18/2013-12/31/2014 (NCE to Dec 31, 2015)“ Establishing in vivo high-density electrophysiological methods to interrogate circuit-level functional
connectivity in genetic mouse models of Autism.”
PI John Foxe, Ph.D.; co-PI, Noboru Hiroi, PhD
Agency, Intellectual Disability Developmental Disorders Research Center, Albert Einstein College ofMedicine; Type, internal grant; Period, 2/1/2014-6/30/2015“The structure and function of neonatal social communication in a mouse model of 16p11.2 copy number
variants.”
PI: Noboru Hiroi, Ph.D.
Agency, Astellas Pharma, Inc.; Type, grant: Period, 2/14/2015-2/13/2016
Pending:
1R01HD084988-01“Identifying the Structure and Function of Social Communication in Autism”
PI: Noboru Hiroi, Ph.D.
Agency, NICHD/NIMH: Type, R01: Period, 7/1/2015-6/30/2020 (Impact score 21; Percentile 11)
Lectures by Invitation over the past 10 years:
International:
March 24, 2005
March 25, 2005

“Chromosome 22q11: Mouse models of schizophrenia”, The National
Institute of Neuroscience, Tokyo, Japan“Chromosome 22q11: Mouse models of schizophrenia”, RIKENGenomic Sciences Center, Yokohama, Japan
6

Noboru Hiroi, Ph.D.
March 24, 2006
October 5, 2007
October 6, 2007

March 25, 2010

April 8, 2010

July 30, 2010

Feb. 16, 2011

March 31, 2011

July 15, 2011

September, 2011

October 27, 2011

October 31, 2011

“22q11.2 Genes and Neuropsychiatric Disorders”, Tokyo Institute of
Psychiatry, Tokyo, Japan“Mouse models of Schizophrenia and Nicotine Dependence”,
Department of Engineering, Waseda University, Tokyo, Japan“Mouse models of Schizophrenia and Nicotine Dependence”, Plenary
lecture, the 67th Japanese Society for Animal Psychology, Tokyo,
Japan“Mouse models of Neuropsychiatric Disorders”, Department of
Psychiatry, National Defense Medical College, Tokorozawa, Saitama,
Japan“Molecular Basis of Nicotine Cue Reactivity”. 12th International
Neuroscience Winter Conference April 6th - April 10th 2010, Sölden,
Austria“Tbx1 heterozygosity impairs hippocampus-dependent reference
memory in mice” Symposium at the 7th International 22q11.2 Deletion
Syndrome Scientific Meeting, July 29-31, 2010, Coventry, UK.
“Nicotine Cue Reactivity: Withdrawal, Seeking, and cGMP-dependent
protein kinase”. Symposium “Tobacco Addiction: Basic Science
Insights on a Multifaceted Disorder. Co-Organizers: Darlene Brunzell
and Paul Clarke. The 2011 Annual Meeting of the Society for Researchon Nicotine and Tobacco. Toronto, Canada“Molecular mechanisms of addiction”, Special Interest Session Chair,
13th International Neuroscience Winter Conference, March 29-April 2,
2011. Sölden, Austria“Heterozygosity ofTbx1 causes phenotypes in social behavior and spatial
and working memory in mice. To be given in a symposium on July 15,
2011. 18th International Scientific meeting of the Velo-Cardio-Facial
Syndrome Educational Foundation, Inc. New Brunswick, NJ, July 1417, 2011.
Deconstructing craving: dissociable anatomical and molecular control ofextinction of nicotine cue reactivity in mice. Symposium, European
Society for Research on Tobacco and Nicotine, Turkey.
“Genetic mouse model of developmental neuropsychiatric disorders”,
Symposium, Annual meeting of the Japanese Society of
Neuropsychopharmacology, Tokyo, Japan, October 27-29, 2011.
“Deconstructing nicotine craving: dissociable anatomical and molecular
control of nicotine cue reactivity in mice.” Hoshi Pharmaceutical
College, Tokyo, Japan

September 26, 2012. “Human chromosome 22q11 and Developmental Neuropsychiatric Disorders”
Hiroshima University, Hiroshima, Japan.
September 28, 2012. “Copy Number Variation: What We Learn from Mouse Models of 22q11.2associated Neuropsychiatric Disorders” Plenary lecture at the 34th Annual
Meeting of the Japanese Society of Biological Psychiatry, Kobe, Japan.
October 2, 2012.
“Human chromosome 22q11 and Developmental Neuropsychiatric Disorders”
RIKEN-BSI, Wako, Japan.

June 22, 2013

“Translating 22q11.2 CNV-associated developmental neuropsychiatricdisorders into mouse models. Neuro2013, Kyoto, Japan

7

Noboru Hiroi, Ph.D.
June 26, 2013

“What 22q11.2 CNV mouse models tell us about mechanisms underlying
developmental neuropsychiatric disorders. Meijo Univeristy, Nagoya, Japan

June 28, 2013

“Copy Number Variation: from rare variants to common mechanisms ofdevelopmental neuropsychiatric disorders” Kyoto University, Kyoto,
Japan
July 20, 2013
“Tbx1 andSept5 contribute to behavioral phenotypes of 22q11.2
associated developmental neuropsychiatric disorders. VCFS Conference,
Dublin, Ireland July 18-21, 2013
February 13, 2014 “Copy Number Variation at 22q11.2: from rare variants to common
mechanisms of developmental neuropsychiatric disorders.” Naha,
Okinawa, Japan Feb 14-16, 2014
February 17, 2014 “Copy Number Variation at 22q11.2: from rare variants to common
mechanisms of developmental neuropsychiatric disorders.” Kyushu
University, Fukuoka, Japan
February 18, 2014 “Copy Number Variation at 22q11.2: from rare variants to common
mechanisms of developmental neuropsychiatric disorders.” Nagoya
University, Nagoya, Japan
June 23, 2014
“Identification of chromosomal segments and individual genes critical fordevelopmental neuropsychiatric disorders in mouse models of 22q11.2 copy
number variants”. College of International Neuropsychopharmacology (CINP)World Congress. Panel session, Vancouver, Canada.

August 5, 2014

Structure of social communication in a mouse model of developmental
neuropsychiatric disorders. Ultrasonic communication in Rodents. 2ndinternational workshop-, University of Tokyo, Tokyo, Japan
August 7, 2014
Human chromosome 22q11.2 and neuropsychiatric disorders. Osaka
University School of Medicine, Osaka, Japan
August 8, 2014
Delving into Brain Mechanisms of Neuropsychiatric Disorders
associated with 22q11.2 Copy Number Variation. RIKEN-BSI, Wako,
Saitama, Japan
August 4, 2015
Nara Medical College, Nara, Japan
August 5, 2015
Kobe University School of Medicine, Kobe Japan
August (TO BE SCHEDULED) Astellas Pharma Research Center, Tsukuba, Japan
August 25, 2015
Forum of Creativity, Tohoku University, Sendai, Japan
National:
September 27, 2005 “Intracellular Molecules of Addiction”, University of Pennsylvania
School of Medicine, Center for Neurobiology and Behavior.
April 13, 2007
“Genes, Molecules and Nicotine Dependence”, University of Southern
California, Los Angeles
January 9, 2008
“Chromosome 22q11: A Cornucopia of Behavioral Genes”, Children’s
Hospital of Philadelphia, University of Pennsylvania School of
Medicine
February 23, 2010 “22q11 and Neuropsychiatric Disorders”. Ground Round, Lincoln
Hospital, Bronx, NY
March 16, 2011
“Autism: 22q11 Bridges Mouse Proxy and Human Correlation.
Departmental seminar series, Department of Neuroscience, Albert
Einstein College, Bronx, NY

8

Noboru Hiroi, Ph.D.
July 7, 2012

July 31, 2012

“Alterations of Social Behavior Through Genetic and Environmental
Manipulation of the 22q11.2 Gene SEPT5 in the Mouse Brain” 8th
Biennial 22q11.2 Deletion Syndrome Meeting. Lake Buena Vista, Florida,
USA - From July 6 – 10, 2012.
“ Human 22q11.2 and Developmental Neuropsychiatric Disorders” Autism
Center of Excellence Summer School Seminar Series. Department of Pediatrics,
Albert Einstein College of Medicine, Bronx, NY

Dec 13, 2012

“Human Chromosome 22q11.2 and Developmental Neuropsychiatric
Disorders” Einstein Internal Faculty Seminar Series, Albert Einstein

Dec 9, 2013

“Tbx1 and Sept5 contribute to behavioral and neuronal phenotypes inmouse models of 22q11.2-associated ASD. Co-Chair of the Panel
Session “Autism Spectrum Disorders: From Rare Chromosomal
Abnormalities to Common Molecular Targets” ACNP meeting.
Hollywood, FA.

May 9, 2014

“Identification of chromosomal segments and individual genes critical for
schizophrenia-related phenotypes in mouse models of 22q11.2 copy number
variants. Symposium at the Annual Meeting of the Society of BiologicalPsychiatry, New York, NY.

July 15, 2014

February 5, 2015

“Identification of chromosomal segments and individual genes criticalfor schizophrenia-related phenotypes in mouse models of 22q11.2 copy
number variants. ACE Internship lecture series, IDDRC, Albert Einstein
College of Medicine, Bronx, NY.
“Delving into Brain Mechanisms of Autism Spectrum Disorders associatedApril 17, 2014

with 22q11.2 Copy Number Variation”. Psychiatry Research Society, Park
City, Utah
“Copy Number Variation at 22q11.2: from rare variants to common

College of Medicine, Bronx, NY

mechanisms of developmental neuropsychiatric disorders” Center of
Neurobiology and Behavior. University of Pennsylvania School of
Medicine, Philadelphia, PA
Faculty Advisor/Mentor:

I have mentored the following students, post-doctoral fellows, and residents in my laboratory:
Post-doctoral fellows
Hongwen Zhu, M.D. Currently Vice Chair, Tianjin Hospital, People’s Republic of China
1998-2000
Dr. Zhu was enrolled in the Graduate Program of the Neuroscience Department in 2000 andgraduated with a PhD in 2007.
Soh Agatsuma, M.D., Ph.D. Currently Professor of Psychiatry, Kobe College, Kobe, Japan
2003-2006, Psychiatry fellow
2006 – 2009, Instructor in the Hiroi laboratory
Dr. Agatsuma was awarded a Ph.D. in 2008 from his alma mater, Osaka University, Japan, based on
the work he completed in my laboratory.
Takehito Sawamura, M.D. Currently Chief Psychiatrist, Lieutenant Commander, Self-Defense Forces
Central Hospital, Japan.
2004 Post-doctoral fellow
9Noboru Hiroi, Ph.D.

Go Suzuki, M.D. Currently a research psychiatrist at Japan Aerospace Exploration Agency (JAXA),
2007-2008, Post-doctoral fellow.
Tomohisa Takahashi, MD Currently Psychiatrist, Department of Psychiatry, National Defense Medical
College, Japan
2012- 2013, Post-doctoral fellow
Akitoyo Hishimoto, MD, PhD. Currently Assistant Professor at Kobe University School of Medicine,Japan
2013-2014, Post-doctoral fellow
Takeshi Izumi, MD, PhD Currently, Lecturer, Department of Psychiatry, Hokkaido University School of
Medicine, Japan
2013-2014, Visiting Scientist
Shuken Boku, MD, PhD Currently Assistant Professor at Kobe University School of Medicine, Japan
July 2012-2014, Post-doctoral fellow
Akira Nishi, 2014 Student at University of Tokushima School of Medicine
2014, Visiting student from University of Tokushima School of Medicine, Japan.
Current
Takeshi Hiramoto, Ph.D. 2008-2009; 2010-present (Associate).
Seiji Abe, Ph.D. 2014-present
Hiroko Nomaru, PhD, 2015-present
Yoshinobu Ishitobi, MD, 2015-present
Yasuhiko Naka, MD, 2015-present
Past Ph.D. Student:
Hongwen Zhu, M.D., Ph.D. (2000-2007) completed his Ph.D. studies in June 2007.
He is currently Vice Chair, Tianjin Hospital, People’s Republic of China.
Daniel Scott, Ph.D. (2004-2011) successfully defended his Ph.D. thesis in March, 2011 and graduated witha PhD on June 1, 2011. He is currently a post-doctoral position at University of Texas Southwestern
Medical School.
Kathryn Harper, PhD (2006- 2012)
She completed her thesis work in 2012 and is currently a post-doctoral fellow at University of North
Carolina.
Advisory Committee
Robert J. Hayes, Ph.D.
Michelle Riley, Ph.D.
10

Noboru Hiroi, Ph.D.
Jordan A. Spector, M.Sc.
Kyle Lapidus, Ph.D.
Mana Mirjany, Ph.D.
Collene Lawhorn, Ph.D.
Thesis Defense Committee
Stanislav R. Vorel, Ph.D.
Robert J. Hayes, Ph.D.
Kyle Lapidus, Ph.D.
Summer research program student:
Ms. Shiry Wagner (2000)
Mr. David Elson (2001)
Ms. Jennie Tenuto (2004)
Intel Talent Search Competition student
Ms. Priya Chordia (2004 Intel Science Talent Search student)
Mr. Brian Rosenberg (2002-2004). Mr. Brian Rosenberg carried out a research project under mysupervision and received the following awards:
1) NY regional finalist and a national semifinalist, the Intel Science Talent Search2) National Winner of the American Academy of Neurology
3) First place, Biology, Tri-County Science Fair

11

Noboru Hiroi, Ph.D.

Bibliography
A. Original Communications in Reviewed Journals:
1. Hiroi, N. and White, N.M. Conditioned stereotypy: behavioral specification of the UCS andpharmacological investigation of the neural change. Pharmacol Biochem Behav 32(1), 249-58, 1989.
2. Hiroi, N. and White, N.M. The reserpine-sensitive dopamine pool mediates (+)-amphetamineconditioned reward in the place preference paradigm. Brain Res. 510(1), 33-42, 1990.
3. White, N.M., Packard, M.G., and Hiroi, N. Place conditioning with dopamine D1 and D2 agonists
injected peripherally and into nucleus accumbens. Psychopharmacol. 103(2), 271-276, 1991.
4. Hiroi, N. and White, N.M. The amphetamine conditioned place preference: differential involvement of
dopamine receptor subtypes and two dopamine terminal areas. Brain Res. 552(1), 141-152, 1991.
5. Hiroi, N. and White, N.M. The lateral nucleus of the amygdala mediates expression of theamphetamine-produced conditioned place preference. J. Neurosci.11(7), 2107-2116, 1991.
6. White, N.M. and Hiroi, N. Pipradrol conditioned place preference is blocked by SCH23390. Pharmacol
Biochem Behav 43(2), 377-380, 1992.
7. Hiroi, N. and White, N.M. The ventral pallidum area is involved in the acquisition, but not expressionof the amphetamine conditioned place preference. Neurosci. Lett. 156(1-2), 9-12, 1993.
8. Xu, M., Moratalla, R., Gold, L.H., Hiroi, N., Koob, G.F., Graybiel, A.M., Tonegawa, S. Dopamine D1
receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediatedbehavioral responses. Cell 79(4), 729-742, 1994.
9. Hiroi, N. Compartmental organization of calretinin in the rat striatum. Neurosci. Lett. 197(3), 223-226,
1995.
10. Chen, J.S., Nye, H.E., Kelz, M.B., Hiroi, N., Nakabeppu, Y., Hope, B.T., Nestler, E.J. Regulation ofdeltaFosB and FosB-like proteins by electroconvulsive seizure and cocaine treatments. Mol.
Pharmacol.48(5), 880-889, 1995.
11. Berhow, M.T., Hiroi, N. and Nestler, E.J. Regulation of ERK (extracellular signal regulated kinase),part of the neurotrophin signal transduction cascade, in the rat mesolimbic dopamine system by chronic
exposure to morphine and cocaine. J. Neurosci.16(15), 4707-4715, 1996.
12. Hiroi, N. and Graybiel, A.M. Atypical and typical neuroleptic treatments induce distinct programs oftranscription factor expression in the striatum. J. Comp. Neurol. 374(1), 70-83, 1996.
13. Berhow, M.T., Hiroi, N., Kobierski, L., Hyman, S.E., Nestler, E.J. Influence of cocaine on the JAKSTAT pathway in the mesolimbic dopamine system. J. Neurosci.16(24), 8019-8026, 1996.
14. Hiroi, N., Brown, J.R., Haile, C.N., Ye, H., Greenberg, M.E., Nestler, E.J. FosB mutant mice: Loss ofchronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine’s psychomotor
and rewarding effects. Proc. Natl. Acad. Sci. USA 94(19), 10397-10402, 1997.
15. Rocha, B.A., Scearce-Levie, K., Lucas, J.J., Hiroi, N., Castanon, N., Crabbe, J.C., Nestler, E.J., Hen,
R. Increased vulnerability to cocaine in mice lacking serotonin1B receptor. Nature 393 (6681), 175-178,
1998.
16. White, N.M. and Hiroi, N. Preferential localization of self-stimulation sites in striosomes/patches in the
rat striatum. Proc. Natl. Acad. Sci. USA 95(11), 6486-6491, 1998.
17. Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W.-J., Snyder, G.L., Nishi, A., Cheramy, A.,
O’Callaghan, J.P., Miller, D.B., Cole, D.G., Corbett, R., Haile, C.N., Cooper, D.C., Onn, S.P., Grace,
A.A., Ouimet, C.C., White, F.J., Hyman, S.E., Surmeier, D.J., Girault, J.A., Nestler, E.J., Greengard, P.
DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281(5378), 838-842,
1998.

12

Noboru Hiroi, Ph.D.
18. Hiroi, N., Marek, G., Brown, J.R., Ye, H., Saudou, F., Vaidya, V.A., Duman, R.S., Greenberg, M.E.,
Nestler, E.J. Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic
electroconvulsive seizures. J. Neurosci. 18(17), 6952-6962, 1998.
19. Carlezon, W.A., Thome, J., Olson, V.G., Lane-Ladd, S.B., Brodkin, E.S., Hiroi, N., Duman, R.S.,
Neve, R.L., Nestler, E.J. Regulation of cocaine reward by CREB. Science 282(5397), 2272-2275, 1998.
20. Hiroi, N., Fienberg, A., Haile, C., Alburges, M., Hanson, G., Greengard, P., Nestler, E.J. Neuronal andbehavioral abnormalities in striatal function in DARPP-32 mutant mice. Eur. J. Neurosci 11(3), 11141118, 1999.
21. Atkins, J.B., Chlan-Fourney, J., Nye, H.E., Hiroi, N., Carlezon, W.A. Jr., Nestler, E.J. Region-specificinduction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs.
Synapse 33, 118-28, 1999.
22. Haile, C.N., Hiroi, N., Nestler, E.J., Kosten, T.A. Differential behavioral responses to cocaine areassociated with dynamics of mesolimbic dopamine proteins in Lewis and Fischer 344 rats. Synapse
41(3):179-90, 2001.
23. Hiroi, N, Martin, AB, Grande, C, Alberti, I, Rivera, A, Moratalla, R. Molecular dissection of dopamine
receptor signaling. J Chem. Neuroanat. 23(4):237-42, 2002. Based on the poster that received the bestposter prize at the 1st International Cajal Club Meeting, Madrid, Spain.
24. Grande, C., Zhu, H., Martin, A.B., Lee, M., Ortiz, O., Hiroi, N., Moratalla, R. Chronic treatment withatypical neuroleptics induces striosomal aggregation of FosB/∆FosB expression in rats. BiologicalPsychiatry 55(5):457-63, 2004.
25. Lee, M, Chen, K., Shih, JC, Hiroi, N. MAO-B knockout mice exhibit deficient habituation of
locomotor activity but normal nicotine intake. Genes, Brain & Behavior. 3(4), 216-227, 2004.
26. Hiroi, N and Agatsuma, S Genetic susceptibility to substance dependence. Molecular Psychiatry
10(4), 336-344, 2005. Feature Review.
27. Zhu, HW, Lee, MS, Guan, F. Agatsuma, S, Scott, D, Fabrizio, K, Fienberg, AA, Hiroi, N. DARPP-32
phosphorylation opposes the behavioral effects of nicotine. Biol. Psychiatry 58(12):981-9, 2005.
28. Hiroi N., Zhu H., Lee M., Funke B., Arai M., Itokawa M., Kucherlapati R., Morrow B., Sawamura T.,
Agatsuma S. A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive
behavioral abnormalities in mice. Proc. Natl. Acad. Sci. USA 102(52), 19132-19137, 2005.
29. Agatsuma S., Lee M., Zhu H., Chen K., Shih J., Seif I., Hiroi N. Monoamine oxidase A knockout mice
exhibit impaired nicotine preference but normal responses to novel stimuli. Human Molecular Genetics
15(18):2721-31, 2006.
30. Zhu H., Lee M., Agatsuma S., Hiroi N. Pleiotropic impact of constitutive fosB inactivation on
nicotine-induced behavioral alterations and stress-related traits in mice. Human Molecular Genetics.
16(7):820-36, 2007
31. Suzuki,G., Harper, K., Hiramoto, T., Lee, M., Kang, G., Kinoshita, M., Tanigaki, M., Buell, M., Geyer,M., Trimble, W., Agatsuma, S., Hiroi, N. Sept5 deficiency exerts pleiotropic influence on social andaffective behaviors and cognitive functions in mice. Human Molecular Genetics, 18(9):1652-60, 2009.
32. Hiroi N. and Scott, D. Constitutional mechanisms of vulnerability and resilience to nicotine
dependence. Molecular Psychiatry 14(7):653-67, 2009. Feature Review.
33. Suzuki, G., Harper,K.M., Hiramoto, T., Funke, B., Lee, M.S., Kang, G., Buell, M., Geyer, M.A.,
Kucherlapati, R., Morrow, B., Männistö, P.T., Agatsuma, S., Hiroi, N. Over-expression of a humanchromosome 22q11.2 segment including TXNRD2, COMT, and ARVCF developmentally affects
incentive learning and working memory in mice. Human Molecular Genetics,18(20):3914-25, 2009.
34. Agatsuma, S., Dang, M.T., Li, Y., Hiroi, N. NMDA receptors on striatal neurons are essential forcocaine cue reactivity in mice. Biological Psychiatry, 67(8):778-80, 2010.

13

Noboru Hiroi, Ph.D.
35. Scott, D and Hiroi, N. Emergence of dormant conditioned incentive approach by conditioned
withdrawal in nicotine addiction. Biological Psychiatry 68(8):726-32, 2010
36. Scott, D and Hiroi, N. Deconstructing craving: dissociable cortical control of cue reactivity in nicotine
addiction. Biological Psychiatry 69(11):1052-9, 2011.
37. Hiramoto, T., Kang, G., Suzuki, G., Satoh, Y., Kucherlapati, R., Watanabe, Y., Hiroi, N. Tbx1:
identification of a 22q11.2 gene as a risk factor for autism spectrum disorder in a mouse model.
Human Molecular Genetics, 20(24):4775-85 2011.
38. Lapidus KA, Nwokafor C, Scott D, Baroni TE, Tenenbaum SA, Hiroi N, Singer RH, Czaplinski K.
Transgenic expression of ZBP1 in neurons suppresses cocaine-associated conditioning. Learning andMemory, 19(2):35-42. 2012.
39. Yoshida A, Yamamoto N, Kinoshita M, Hiroi N, Hiramoto T, Kang G, Trimble WS, Tanigaki K,
Nakagawa T, Ito J. Localization of septin proteins in the mouse cochlea. Hear Res. 289(1-2):40-51,
2012 PMID:22575789
40. Harper, K.M., Hiramoto, T., Tanigaki, K., Kang, G., Suzuki, G., Trimble, W., Hiroi, N. Alterations of social
interaction through genetic and environmental manipulation of the 22q11.2 gene Sept5 in the mouse brain.
Human Molecular Genetics 21(15): 3489-3499, 2012 PMID:22589251
41. Hiroi, N., Hiramoto, T., Harper, K.M., Suzuki, G., Boku, S. Mouse Models of 22q11.2-associated Autism
Spectrum Disorder. Autism S1:001, 1-9, 2012, http://dx.doi.org/10.4172/2165-7890.S1-001

42. Hiroi, N., Takahashi, T., Hishimoto, A., Izumi, A. Boku, S., Hiramoto, T. Copy Number Variation at
22q11.2: from rare variants to common mechanisms of developmental neuropsychiatric disorders.
Molecular Psychiatry 18: 1153-1165, 2013.
43. Hiroi, N. Small Cracks in the Dam: Rare genetic variants provide opportunities to delve intomechanisms of neuropsychiatric disorders. Biological Psychiatry 76(2):91-2, 2014.
44. Boku, S., Toda, H., Nakagawa, S, Kato, A., Inoue, T., Koyama, K., Hiroi, N., Kusumi, I. Neonatal
maternal separation alters the capacity of adult neural precursor cells to differentiate into neurons via
methylation of retinoic acid receptor gene promoter. Biological Psychiatry 77(4) 335-344, 2015.
45. Takahashi, T., Okabe, S., Ó Broin, P., Nishi, A., Ye, K., Beckert, M.V., Izumi, T., Machida, A., Kang,
G., Pena, JL., Golden, A., Kikusui, K., Hiroi, N. Structure and function of neonatal social
communication in a genetic mouse model of autism (submitted)
B. Books, Chapters in Books, and Review Articles:
Peer-reviewed Review Articles:
1. White, N.M. and Hiroi, N. Amphetamine cue preference and the neurobiology of drug-seeking. Sem.
Neurosci. 5, 329-336, 1993.
2. Agatsuma, S, Hiroi, N. Genetic basis of drug dependence and comorbid traits. Japanese Journal of
Neuropsychopharmacology 24(3), 137-145, 2004.
3. Agatsuma, S and Hiroi, N. Chromosome 22q11 and schizophrenia. Japanese Journal of
Neuropsychopharmacology 25(2), 79-84, 2005.
4. Hiroi, N. Mouse models of neuropsychiatric disorders: schizophrenia and nicotine dependence.
Japanese J. Animal Psychology 58 (1), 33-39 (2008). Based on the plenary lecture given at the 67th
Japanese Society for Animal Psychology, Tokyo, Japan, October 6, 2007.
Books and Chapters in Books
5. Hiroi, N., Chen, J.S., Nye, H.E., Nestler, E.J. Chronic FRAs: Novel transcription factors regulated in
the basal ganglia by chronic neuronal perturbations. In The Basal Ganglia. V. (C. Ohye, M. Kimura,
J.S. McKenzie, eds.). Plenum Press, New York, 1996.

14

Noboru Hiroi, Ph.D.
6. Hiroi, N. and Nestler, E.J. Nuclear memory: Gene transcription and behavior. In Advances inPharmacology 42, 1037-1041, 1998.
7. Hiroi, N. Dependence, tolerance, and alteration in gene expression. In Marihuana and Medicine. (G. G.
Nahas, K.M. Sutin, Harvey, D., Agurell, S. eds.). Humana Press. Totowa, New Jersey, 1999.
8. Hiroi, N. and Nishi, A. Dimensional deconstruction and reconstruction of CNV-associatedneuropsychiatric disorders. In Modeling the psychopathological dimensions of schizophrenia andrelated psychoses (M. Pletnikov and J.L. Waddington, eds). Handbook of Behavioral Neuroscience
Series, Elsevier (in press, 2015).
9. Nishi, A. Hiroi, N Genetic mechanisms emerging from mouse models of CNV-associatedneuropsychiatric disorders. In: The Neurobiology of Schizophrenia. Edited by (T. Abel, PhD and T.
Nickl-Jockschat, MD, eds) Elsevier (in press, 2015).

15